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This investigation was prompted by the findings that (1) dibucaine-resistant 
homozygotes and heterozygotes for  plasmacholinesterase also exhibit resis- 
tance to fluoride inhibition, (2) the differentiation o f  dibucaine-resistant 
f r o m  the fluoride-resistant genotypes is ambiguous with the method o f  
Harris and Whittaker, (3) the plasmacholinesterase inhibition by Na fluo- 
ride (FN) is markedly influenced by the temperature. Therefore, we modi- 
f i ed  their method by increasing (1) the temperature o f  the reaction from 25C 
to 37C and (2) the concentration o f  Na fluoride f rom 5.0 x 10 -5 M to 2.5 x 
10 -4 g.  With this method, genetically normal individuals have a mean F N  +_ 
sD = 77.0 +_ 3.22 while atypical dibucaine-resistant homozygotes have a 
mean F N  +_ so = 43.0 +_ 10.0 and atypical dibucaine-resistant heterozygotes 
67.0 +_ 5.37. Since a linear correlation was observed between D N and FAr by 
our new method, a fluoride number 2 SD lower than the predicted FN  f rom 
the DN  can distinctly identify the fluoride-resistant plasmacholinesterase 
genotype E f. 
KEY WORDS: FN determination; plasmacholinesterase; EY~ genotype; enzyme assay; modified 
FN. 
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INTRODUCTION 
Harris and Whittaker (1961) claimed that a new phenotype of human serum 
cholinesterase was recognized by sodium fluoride inhibition. Since this 
original report, the method of Harris and Whittaker has been accepted as a 
standard method for the determination of fluoride-resistant plasmacholines- 
terase (Whittaker, 1967, 1968; Thompson and Whittaker, 1966; Whittaker 
and Vickers, 1970). These authors utilized 5.0 × 10 -5 M concentration of Na 
fluoride at 25C. Under these conditions of essay, a normal person has FN < 
64 while a fluoride-resistant homozygote E~E f) has FN < 34. 
After the adaptation of the method for FN determination according to 
Harris and Whittaker, we early recognized that the narrow percentage ranges 
of inhibition in the various genotypes with the use of 5.0 × 10 -5 M Na fluoride 
concentration did not allow a clear differentiation of the genotypes. There- 
fore, a great overlap existed between the various genotypes based on the 
concomitant determination of DN by the method of Kalow and FN by the 
method of Harris and Whittaker. Subsequently we recognized that individu- 
als with dibucaine resistance also exhibited fluoride resistance and vice versa 
at both 25 and 37 C utilized by Foldes et al. (1963) for the determination of 
DN. Although the increase in temperature from 25 to 37 C caused only 
predictable and minor changes in DN, it markedly influenced the FN. In 
order to improve the selectivity and accuracy of FN determination, our study 
was undertaken. 
MATERIALS AND METHODS 
Source of Enzymes 
Freshly obtained venous heparinized blood samples were separated by centrif- 
ugation at 2600 rpm into red cells and plasma. The supernatant plasma was 
immediately separated from the buffy coat and stored at - 2 0  C or immedi- 
ately utilized. The hydrolysis rate of benzoylcholine chloride commercially 
obtained from Calbiochem (Pasadena, California) was determined by 
Kalow's ultraviolet spectrophotometric method at 25, 31, and 37 C as 
indicated in the figures. The influence of dibucaine hydrochloride, sodium 
fluoride, and RO2-0683 [2-hydroxy-5-phenylbenzyl trimethylammonium 
(bromide) dimethylcarbamate] on the hydrolysis of benzoylcholine chloride 
was determined, and pI-inhibition curves were plotted as shown in Results. 
Each point represents the mean of three determinations checking within 5%. 
Based on the pI-inhibition curves, a concentration of Na fluoride was selected 
which gives 75% inhibition of benzoylcholine hydrolysis rate. In addition, 
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RO2-0683 was utilized to confirm the dibucaine resistant genotypes as 
reported by Foldes et al. (1963). Three plasma samples of suspected or 
claimed fluoride-resistant plasma cholinesterase genotypes were also studied 
and the pI-inhibit ion curves of the three inhibitors determined at 37 C. 
RESULTS 
The p I  inhibition curves of Na  fluoride at 37 C and 25 C in the plasma of 
normal E~E~ and atypical dibucaine-resistant homozygotes E~E~ are shown 
in Fig. 1. It is evident that increasing the reaction temperature from 25 to 
37 C results in a markedly reduced FN. It  can also be observed that there is a 
marked difference in the/50 between the E~E~ and E~E~. It is evident from the 
curve that the use of 5.0 × l0 -5 M concentration at either 25 or 37 C may 
result in a very large experimental error because this concentration falls on 
the mid portion of the pI-inhibit ion curve where the slope is the greatest. 
Figures 2 and 3 summarize the results obtained with dibucaine and 
RO2-0683. As can be observed in Fig. 2, the influence of temperature on the 
pI- inhibi t ion curve of dibucaine is small. Consequently, changing the temper- 
ature from 25 to 37 C results in only a few units of change in DN. It should 
also be noted that 1 x 10 -5 M dibucaine concentration falls on the flattening 
portion of the pI-inhibit ion curve; therefore, errors in dibucaine concentra- 
tion will lead to a little experimental error in D N  determination. Similarly the 
pI- inhibi t ion curve of RO2-0683 was little affected by temperature change, 
as Fig. 3 illustrates. 
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Fig.  I .  Effect  of t empe ra tu r e  on the  in vitro inhibi t ion of normal  and  a typ ica l  homozygous  
p l a smacho l ines t e ra se  by sodium fluoride. 
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Fig. 2. Effect of temperature on the in vitro inhibition of normal and atypical homozygous 
plasmacholinesterase by dibucaine hydrochloride. 
A distinct differentiation of the various genotypes can be achieved by the 
utilization of the pI-inhibit ion curves of dibucaine, sodium fluoride, and 
RO2-0683 in combination. In this way, three claimed E~E f variants were 
unquestionably identified as E~E~ or E~E~. Figure 4 shows such an example 
of  E~E7 who was erroneously classified as a fluoride-resistant heterozygote 
E~E{ (compare Fig, 2 to Fig. 4). Figure 5 shows the effect of sodium fluoride 
on the cholinesterase of the same E~E+t (compare Fig. 5 to Fig. 1). 
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Fig.  3. Effect of t empera tu re  on the in vi tro inhibi t ion of normal  and  a typ ica l  homozygous  
plasmacholinesterase by RO2-0683. 
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Fig. 4. Identification of the genotype of plasma cholinesterase by the pI-inhibition curve for 
dibucaine in a questionable subject. 
DISCUSSION 
Since the discovery of fluoride-resistant genotype by Harris and Whittaker 
(1961), it has become increasingly evident that the differentiation of fluoride 
resistant from the dibucaine-resistant genotypes by this method was inaccu- 
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Fig. 5. Identification of the genotype of plasmacholinesterase by the pl-inhibition curve for 
sodium fluoride in a questionable subject. 
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Fig. 6. DN and FN reported in 390 apneic patients with various atypical genotypes of 
plasmacholinesterase. Data plotted from Whittaker and Vickers (1970). 
rate as is illustrated in Fig. 6. This figure contains all data points reported by 
Whittaker and Vickers (1970) from 390 apneic patients collected from the 
world literature. When these results were replotted, it became evident that 
based only on the DN and FN by the Harris and Whittaker method, 
genotypes E~E~ and E~E~ can be erroneously identified because of the overlap 
DN and FN values in these two groups. Furthermore, E~E~ cannot be 
distinguished from E~E~, since both FN and DN are intermediary, and the 
expected FNs fall between the values for normal homozygotes (E~E~) and 
dibucaine-resistant homozygotes (E~E~), as seen in Fig. 6. 
That dibucaine-resistant homozygotes and heterozygotes also have an 
abnormally low FN was recently well established by Kothary et aL (1979). 
By the aid of a correlation equation between DN and FN, FN = 0.59 DN + 
32, one can predict the FN in a dibucaine-resistant E7 variant. No such 
fluoride-resistant variant (E~) was observed in 144 probands and their 
relatives referred to our laboratory, since none deviated from this equation. In 
order to clearly identify the genotypes containing an E~ component, one is 
forced to resort to the plotting of the pI-inhibition curve of dibucaine, Na 
fluoride, and RO2-0683 in the plasma samples of each individual claimed to 
be a fluoride-resistant phenotype. In three questionable E~ variants, the 
pI-inhibition curves using dubucaine, Na fluoride, and RO2-0683 clearly 
established that they were atypical dibucaine-resistant genotypes; one exam- 
ple is shown in Fig. 4. 
Although it was claimed that phenotypes with an E~ variant have 
prolonged apnea following succinylcholine by Harris and Whittaker (1961) 
and Whittaker and Vickers (1970), one should confirm the existence of such 
an E~ variant by the pI-inhibition curve, and/or simply by the determination 
of FN by our improved method, before one accepts such a cause-effect 
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re la t ionship .  Erroneous identif icat ion of a d ibuca ine- res i s tan t  var ian t  as 
f luor ide-res is tant  m a y  lead to an erroneous assumpt ion  tha t  the  la t te r  var ian t  
is responsible  for the  prolonged apnea  following succinylcholine.  In order  to 
fac i l i t a te  the correct  identif icat ion of  E~ var iant ,  we r ecommend  the ut i l iza-  
t ion of our modified method  for the de te rmina t ion  of  FN.  
C O N C L U S I O N  
Based on the enzyme kinet ic  studies repor ted  in this ar t icle ,  we recommend  
the  use of  2.5 x 10 -4 M N a  fluoride concentra t ion  which causes 75% 
inhibi t ion  of  the p lasmachol ines te rase  in E~E~ at  37C or body t empe ra tu r e  
ins tead  of  room t empera tu re  in order  to c lear ly  ident i fy  the so-called 
f luor ide-res is tant  genotypes.  The  improved select ivi ty of  our modified method 
for  F N  allows an accura te  identif icat ion of  the  f luor ide-res is tant  genotypes  of 
p lasmachol ines te rase .  
A C K N O W L E D G M E N T S  
W e  are  gra teful  to Ciba  Pha rmaceu t i ca l s  of Summi t ,  New Jersey,  for the 
generous  supply  of  d ibuca ine  hydrochlor ide  (nuperca ine  hydrochlor ide)  and 
to I lhan  Tuzel,  M.D. ,  and  Hoffman La  Roche,  Nut ley ,  New Jersey,  for their  
con t inued  supply of  RO2-0683 and for their  generous gifts which made  these 
invest igat ions  possible. 
R E F E R E N C E S  
Foldes, F, F., Erdos, E. G., Zsigmond, E. K., and Zwartz, J. A. (1960). Reactivation of 
neostigmine inhibited human plasma cholinesterase. J. Pharmacol. Exp. Ther. 129:394. 
Foldes, F. F., Foldes, V. M., Smith, J. C., and Zsigmond, E. K. (1963). The relation between 
plasma cholinesterase and prolonged apnea caused by succinylcholine. Anesthesiology 
24:208. 
Harris, H., and Whittaker, M. (1961). Differential inhibition of human serum cholinesterase 
with fluoride: Recognition of two new phenotypes. Nature 191:496. 
Kothary, S. P., Flynn, K. B., and Zsigmond, E. K. (1979). Fluoride inhibition in patients with 
atypical dibucaine resistant plasmacholinesterase, Biochem. Genet. 17:1169. 
Thompson, J. C., and Whittaker, M. (1966). A study of the pseudocholinesterase in 78 cases of 
apnea following suxamethonium. Acta Genet. Stat. Med. 16:209. 
Whittaker, M. (1967). The pseudocholinesterase variants: A study of fourteen families selected 
via the fluoride resistant phenotype. Acta Genet. Stat. Med. 17:1. 
Whittaker, M. (1968). The pseudocholinesterase variants: Esterase levels and increased resis- 
tance to fluoride. Acta Genet. Stat. Med. 18:325. 
Whittaker, M., and Vickers, M. D. (1970). Initial experiences with the cholinesterase research 
unit. Br. J. Anaesthesiol. 42:1016. 
Zsigmond, E. K. (1973). Fluoride numbers. Letter to the Editor, Br. J. Anaesth. 45:1053. 
Zsigmond, E. K., Flynn, K. B., Matsuki, A., et al. (1973). Atypical plasmacholinesterase as a 
cause of prolonged apnea 10 years experience with plasma cholinesterase laboratory. 
Abstracts of Papers, ASA Annual Meeting, October 7-11. 
